Aurinia Pharmaceuticals Inc. (AUPH) trades at a trailing P/E of 7.4, forward P/E of 19.8. Trailing earnings yield is 13.54%, forward earnings yield 5.06%. PEG 1.03. Graham Number is $14.42.
Criteria proven by this page:
Overall SharesGrow Score: 78/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.2 | -0.23 | 2.06 | 428.32 | - |
| 2017 | -5.3 | -0.13 | 2.25 | 888.22 | - |
| 2018 | -9.0 | 0.52 | 5.14 | 1,248.84 | - |
| 2019 | -21.3 | -0.28 | 6.31 | 5,926.62 | - |
| 2020 | -16.0 | 0.46 | 4.02 | 32.69 | - |
| 2021 | -16.3 | -0.27 | 6.18 | 64.88 | - |
| 2022 | -5.7 | 0.12 | 1.51 | 4.57 | - |
| 2023 | -16.5 | 0.57 | 3.41 | 7.34 | - |
| 2024 | 223.3 | -2.08 | 3.40 | 5.46 | - |
| 2025 | 7.5 | 0.00 | 3.69 | 7.57 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.66 | $173K | $-23.3M | -13465.3% |
| 2017 | $-0.92 | $420K | $-70.79M | -16855.2% |
| 2018 | $-0.76 | $463K | $-64.12M | -13848.8% |
| 2019 | $-1.33 | $318K | $-123.85M | -38945.3% |
| 2020 | $-0.87 | $50.12M | $-102.68M | -204.9% |
| 2021 | $-1.40 | $45.61M | $-180.97M | -396.8% |
| 2022 | $-0.76 | $134.03M | $-108.18M | -80.7% |
| 2023 | $-0.54 | $175.51M | $-78.02M | -44.5% |
| 2024 | $0.04 | $235.13M | $5.75M | 2.4% |
| 2025 | $2.07 | $283.06M | $287.2M | 101.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.81 | $0.68 – $0.99 | $326.22M | $318.61M – $339.67M | 4 |
| 2027 | $1.06 | $0.67 – $1.46 | $383.51M | $366.2M – $412.58M | 3 |
| 2028 | $1.27 | $0.43 – $2.12 | $443.41M | $426.36M – $484.53M | 4 |
| 2029 | $1.26 | $1.19 – $1.41 | $466.27M | $448.35M – $509.51M | 2 |
| 2030 | $1.64 | $1.56 – $1.84 | $517.12M | $497.25M – $565.08M | 2 |
